Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Follicular Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Welcome to The Follicular Lymphoma (FL) Channel

VJHemOnc is excited to introduce The Follicular Lymphoma (FL) Channel, providing you the latest in follicular lymphoma presented at major international congresses by world-renowned experts. Keep updated in the field with exclusive video interviews, podcasts and roundtable discussions.

In addition to perspectives in promising treatments including CAR-T and epigenetic therapeutics, The Follicular Lymphoma Channel covers exciting clinical trial data, current management strategies, and discussion of unmet needs within FL.

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
Considering the impact of lymphoma therapies on the long-term quality of life of patients 2:12
Considering the impact of lymphoma therapies on the long-term quality of life of patients
Ariela Noy • 3 Sep 2025
The need to refine the definition of nodal-based lymphomas 1:18
The need to refine the definition of nodal-based lymphomas
Laurence de Leval • 27 Sep 2025
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL 18:55
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
Elizabeth Budde et al. • 28 Sep 2025
Novel therapies and ongoing trials in NHL: advances in antibody-based combinations 15:43
Novel therapies and ongoing trials in NHL: advances in antibody-based combinations
Gilles Salles et al. • 27 Sep 2025
Genomic determinants of follicular lymphoma precursor conditions 2:36
Genomic determinants of follicular lymphoma precursor conditions
Sandrine Roulland • 18 Sep 2025
Promising results of the MorningSun trial: mosunetuzumab in various lymphoma subtypes 1:19
Promising results of the MorningSun trial: mosunetuzumab in various lymphoma subtypes
Tara Graff • 3 Sep 2025
Challenges & opportunities in bringing bispecifics & CAR T-cells into the community 1:27
Challenges & opportunities in bringing bispecifics & CAR T-cells into the community
Tara Graff • 3 Sep 2025
The potential of bispecific antibody-based combinations to improve outcomes in patients with FL 5:41
The potential of bispecific antibody-based combinations to improve outcomes in patients with FL
Lorenzo Falchi • 5 Sep 2025
Insights into the potential value of epcoritamab in third-line DLBCL & FL 1:04
Insights into the potential value of epcoritamab in third-line DLBCL & FL
Tara Graff • 3 Sep 2025
Tracking responses with ctDNA in patients with FL receiving treatment in the LEVERAGE trial 4:07
Tracking responses with ctDNA in patients with FL receiving treatment in the LEVERAGE trial
Chan Yoon Cheah • 14 Jun 2025
Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL 1:42
Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL
Chan Yoon Cheah • 14 Jun 2025
Findings of an MAIC comparing epcoritamab and mosunetuzumab for R/R FL 1:48
Findings of an MAIC comparing epcoritamab and mosunetuzumab for R/R FL
Alexey Danilov • 13 Jun 2025
The potential value of ultra-low-dose radiation therapy for lymphoma treatment 1:42
The potential value of ultra-low-dose radiation therapy for lymphoma treatment
Lena Specht • 19 Jun 2025
Non-Hodgkin lymphoma highlights from EHA 2025: bispecifics and CAR T-cells 1:42
Non-Hodgkin lymphoma highlights from EHA 2025: bispecifics and CAR T-cells
Umberto Vitolo • 14 Jun 2025
Acalabrutinib in combination with rituximab & lenalidomide in R/R follicular lymphoma 1:27
Acalabrutinib in combination with rituximab & lenalidomide in R/R follicular lymphoma
Paolo Strati • 19 Jun 2025

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals